中国已在30个省份推出了鲁索替尼白癜风药膏，目前已有1000家诊所和1300家药房发放。 China launched ruxolitinib cream for vitiligo in 30 provinces, with 1,000 clinics and 1,300 pharmacies now dispensing it.

2026年3月12日,中国医疗系统控股公司宣布,其子公司Dermavon在中国30个省实现了磷酸盐奶油(Lumirix)的初步处方,该奶油是JAK对维利戈的热门抑制剂。 On March 12, 2026, China Medical System Holdings announced that its subsidiary Dermavon achieved initial prescriptions for ruxolitinib phosphate cream (Lumirix®), a topical JAK inhibitor for vitiligo, across 30 provincial regions in China. 该药物于2026年1月30日获得批准,现已在包括主要皮肤病中心在内的约1 000个医疗机构以及1 300多个离线药房和JD.com提供。 The drug, approved on January 30, 2026, is now available in about 1,000 medical institutions, including major dermatology centers, and through over 1,300 offline pharmacies and JD.com. 它自2023年8月在海南试点使用以来迅速推出,在中国新年期间,通过简化监管程序、真实世界数据和高效率的海关清关,得以实现。 Its rapid rollout followed pilot use since August 2023 in Hainan and was enabled by streamlined regulatory processes, real-world data, and efficient customs clearance during the Chinese New Year.